



Pharmacy and Therapeutics (P&T) Committee Meeting

August 9, 2016

6:00-8:00 p.m.

AGENDA

- | | |
|--|-----------------------|
| I. Welcome | Lotta Crabtree, JD |
| II. Introductions | Lotta Crabtree, JD |
| III. Conflict of Interest Statement | Lotta Crabtree, JD |
| IV. Minutes from February 16, 2016 meeting | Lotta Crabtree, JD |
| V. SHP Update | Lotta Crabtree, JD |
| <ul style="list-style-type: none"> ○ 2017 Benefits ○ Transition of Specialty Medication from Rx to Medical | |
| VI. Old Business | Terracer Earnest, RPh |
| <ul style="list-style-type: none"> ○ PA Program Updates ○ Generic Products available | |
| VII. Light Meal | |

Executive Session (Closed to members only)

- | | |
|--|--|
| VIII. Program Review and Opportunities - 6/1/16 New Policies | |
| <ul style="list-style-type: none"> ○ Short Acting Inhaled Beta Agonist ST ○ Endothelin Receptor Antagonist ○ Colony Stimulating ○ Gabapentin ○ Prostate Cancer Oral Agent ○ Cinqair ○ Oncology – Cabometyx ○ Ocaliva | <ul style="list-style-type: none"> John Anderson, MD John Anderson, MD Michael Spiritos, MD David Konanc, MD Michael Spiritos, MD Jennifer Burch, PharmD Michael Spiritos, MD Jennifer Burch, PharmD |
| IX. New Drug Reviews (May Add, Must Add, Must Not Add) | |
| <ul style="list-style-type: none"> ○ Briviact ○ Nucala ○ Vistogard | <ul style="list-style-type: none"> David Konanc, MD Jennifer Burch, PharmD Jennifer Smith, PharmD |

- Xuriden
- Uptravi
- Zepatier
- Tecentriq
- Cabometyx
- Ocalvia
- Ultravate Lotion
- Otovel

Michael Spiritos, MD
John Anderson, MD
John Engelmann, MD
Michael Spiritos, MD
Michael Spiritos, MD
Jennifer Burch, MD
Joseph Shanahan, MD
Jamilah Brunson, PharmD

X. Other Topics

- Utilization Management (UM) Program Changes
- Formulary Exclusion Exceptions Process
- Change in Tier Recommendations
- Specialty Copay Card

Julie Younkin, PharmD